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The domestic pig is an important large animal model for preclinical testing of novel cell therapies. Recently, we
produced pluripotency reporter pigs in which the Oct4 promoter drives expression of the enhanced green
fluorescent protein (EGFP). Here, we reprogrammed Oct4-EGFP fibroblasts employing the nonviral Sleeping
Beauty transposon system to deliver the reprogramming factors Oct4, Sox2, Klf4, and cMyc. Successful repro-
gramming to a pluripotent state was indicated by changes in cell morphology and reactivation of the Oct4-EGFP
reporter. The transposon-reprogrammed induced pluripotent stem (iPS) cells showed long-term proliferation in
vitro over > 40 passages, expressed transcription factors typical of embryonic stem cells, including OCT4, NA-
NOG, SOX2, REX1, ESRRB, DPPA5, and UTF1 and surface markers of pluripotency, including SSEA-1 and TRA-
1-60. In vitro differentiation resulted in derivatives of the 3 germ layers. Upon injection of putative iPS cells
under the skin of immunodeficient mice, we observed teratomas in 3 of 6 cases. These results form the basis for
in-depth studies toward the derivation of porcine iPS cells, which hold great promise for preclinical testing of
novel cell therapies in the pig model.
Introduction
The seminal discovery of induced pluripotent stem (iPS)cells in the mouse using 4 exogenous transcription factors
paved the way for a novel source for stem cells with a sig-
nificant potential for cell therapies [1]. Subsequently, human
iPS cells were produced by using viral vectors carrying Oct4,
Sox2, Klf4, and cMyc [2–5] or OCT4, SOX2, NANOG, and
LIN28 as reprogramming factors [6]. Successful gene therapy
experiments in mouse models of sickle cell thalassemia dis-
ease, muscular dystrophy, and tyrosinemia demonstrate
the great potential of iPS cell-derived therapeutic treatments
[7–9].
However, the use of retro- or lentiviral vectors for repro-
gramming prohibits the use of these cells for therapeutic
applications in human patients, attributed to risks of inser-
tional mutagenesis and potential oncogene activation [10].
Reprogramming methods, which avoid integration of the
vectors into the host genome have been assessed in murine
and human cells, including nonintegrating adenoviruses
[11,12], episomal DNAs [13–15], or substitution of repro-
gramming factors by small molecules [16,17].
A limitation of murine models for preclinical assessments
of potential cell therapies is the short life span, small size,
and the high level of inbreeding in this species. The pig is an
attractive large animal model for preclinical testing of safety
and efficacy of iPS-based cell therapies. Porcine organs are
largely similar in size and physiology to their human
counterparts rendering the domestic pig a suitable model in
transplantation, immunology, and surgery [18–23]. The
availability of pluripotent porcine cells would be invaluable
for preclinical testing of novel cell therapies. Despite nu-
merous attempts, the derivation of authentic pluripotent
porcine cells has been met with limited success [24]. Only
recently, putative porcine iPS cells fulfilling several criteria
of true pluripotent cells were reported after reprogramming
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fibroblasts with viral vectors [25–28]. Notably, in one study,
chimeric offspring were reported [28]. After breeding of
chimeric pigs, 2 out of 43 F1 offspring carried some of the
reprogramming factors in their genome, suggesting germ
line transmission [29]. However, current data indicate that
reprogramming and in vitro culture conditions are deficient
for induction and maintenance of pluripotency in porcine
iPS cells [24,30–32]. In contrast to other species, in the pig,
the continuous expression of the exogenous transgenic
transcription factors is still necessary to maintain the plu-
ripotent phenotype of presumptive porcine iPS cells [25–
28]. Porcine iPS cells in which the exogenous reprogram-
ming factors are silenced and pluripotency is maintained by
the endogenous pluripotency factors have not yet been re-
ported.
Here, we have applied the Sleeping Beauty (SB) transposon
system for induction of pluripotency in porcine somatic cells.
Recently, we have shown that the SB system, employing a
hyperactive transposase variant [33], is an efficient nonviral
tool for transgenesis in the pig [34,35]. An apparent advan-
tage of SB-catalyzed transgenesis is the preferential integra-
tion into transcriptionally permissive genomic loci [36]. In
contrast, random transgenesis frequently resulted in silenced
transgenes in the pig [37]. Importantly, the SB transposase
has a close-to-random insertion profile in mammalian ge-
nomes [33]. The majority of SB insertions occurs in intergenic
regions, unlike retro- and lentiviral integrations, which favor
promoter and exonic regions [10,12,13]. Thus, the SB-
catalyzed DNA integration reduces the risk of insertional
mutagenesis and represents a rather safe method of gene
delivery [33,36].
Here, fibroblasts of Oct4-enhanced green fluorescent pro-
tein (EGFP) transgenic pigs were applied to monitor the re-
programming process. The Oct4-EGFP pigs carry the entire
18 kb genomic locus of the murine Oct4, which is one of the
best characterized genes involved in pluripotency, control-
ling expression of an EGFP reporter [38–40]. In Oct4-EGFP
pigs, the EGFP expression was found to be restricted to
pluripotent cells of the germ line [41]. Importantly, EGFP
expression was re-activated after experimental reprogram-
ming by either somatic cell nuclear transfer (SCNT), fusion of
porcine somatic cells with murine embryonic stem (ES) cells,
or viral transduction with a set of 4 reprogramming factors
[41]. Here, we employed porcine Oct4-EGFP transgenic
fibroblasts and a SB transposon-based reprogramming
approach to generate pluripotent iPS cells.
Materials and Methods
Plasmid construction
The PB-CAG.OSKM-puDtk sequences containing the
cDNAs of the open reading frames of the 4 Yamanaka factors
(murine Oct4, Sox2, Klf4, and cMyc) were removed from
piggyBac (PB) vectors described previously [42] by NheI and
NotI restriction and cloned into the SpeI and NotI sites of the
pT2HB SB vector. The resulting construct contained a cyto-
megalovirus enhancer, chicken beta-actin hybrid promoter-
driven reprogramming cassette (the reprogramming factors
were combined into a single open reading frame separated
by sequences encoding viral self-cleaving peptide of foot-and
mouth-virus (2A) peptides and a puDtk cassette), flanked by
SB inverted terminal repeats (ITRs).
Derivation of Oct4-EGFP transgenic porcine
fetal fibroblasts
The Oct4-EGFP transgenic pigs were produced by SCNT
and transferred as reconstructed zygotes to synchronized
recipients [41]. One pregnant recipient was sacrificed at day
25 of gestation and fetuses were recovered for fibroblast
derivation as described [43]. Porcine fetal fibroblasts were
cultured in a high-glucose Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% heat-inactivated
fetal calf serum (PAA), 2mM L-glutamine, 1mM sodium
pyruvate, 1% nonessential amino acids, 0.05mM b-mercap-
toethanol, 100U/mL penicillin, and 100mg/mL streptomy-
cin. Cells at passage 3 were used for electroporation with
transposon plasmids. A Biorad electroporator with square
wave function was used for electroporation. For feeder
cells, murine embryonic fibroblasts (MEFs) or transformed
mouse fibroblast cells with expression of leukemia inhibitory
factor (SNL) cells were grown to subconfluency and in-
activated with 10 mg/mL mitomycin C (Sigma) followed by
thorough washings.
iPS cell generation and cultivation
Presumptive iPS cells were cultured in a human ES cell
medium consisting of DMEM/nutrient mixture F-12 sup-
plemented with 20% knockout serum replacement (Milli-
pore), 1mM L-glutamine, 0.1mM nonessential amino acids
(Gibco), 0.1mM b-mercaptoethanol (Sigma), 100U/mL peni-
cillin, 100mg/mL streptomycin, and 4ng/mL basic fibroblast
growth factor (bFGF) (Peprotech). Presumptive porcine iPS
cells were cultured in a humidified atmosphere consisting of
5% CO2 in air at 37C. Gelatinized plates, or plates seeded
with inactivated MEFs or SNLs were used for porcine iPS cell
culture. For subpassaging, a mechanical splitting method [27]
was employed. In brief, a Pasteur pipette was pulled over a
gas burner, in a second step, the tip was bended by 45–60
over a burner. The bended Pasteur pipette was used to scrape
the surface of iPS culture dishes. Typically, small aggregates of
cells were released; then a fresh iPS medium was added and
cell aggregates were subpassed (1:2 to 1:4 ratio) to gelatinized
culture dishes. For gelatinization, the intended culture dishes
were wetted with sterile 1% gelatin in phosphate-buffered
saline (PBS) and allowed to dry immediately before sub-
passaging. Alternatively, porcine iPS cells were passaged on
feeder cells seeded the day before.
Fluorescence microscopy
For fluorescence microscopy, images were made with an
Olympus BX 60 (Olympus) fluorescence microscope equip-
ped with a 12-bit digital camera (Olympus DP 71).
Transmission electron microscopy
Putative iPS cell colonies from passage 16 were mechani-
cally harvested for ultrastructural evaluation. Specimens
were fixed in 3% glutaraldehyde in 0.1M Na phosphate
buffer (pH 7.3) at room temperature for 1 h, and then
transferred and stored in 0.1M Na phosphate buffer at 4C.
Samples were embedded in Bacto-agar (Difco Laboratories),
dehydrated, and embedded in Epon TAAB 812 Embedding
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resin (VWR), and processed for semithin and ultrathin sec-
tions as previously described [44]. Semithin sections were
observed using brightfield microscopy (Leica Microsystems)
and ultrathin sections were observed under a transmission
electron microscope (CM100; Philips).
In vitro differentiation assays
iPS cells were trypsinized and resuspended in the regular
ES cell medium (without bFGF) for generation of embryoid
bodies (EBs). To induce EB formation, the hanging-drop
method was used and drops of 20mL containing 600 cells
were pipetted onto the lids of 10-cm cell culture dishes and
incubated at 37C for 3 days. EBs were washed off the plate
with PBS and transferred to 10-cm dishes containing the ES
cell medium in which they were incubated for 3 additional
days before harvesting.
For ectodermal differentiation [45], iPS cells underwent 3
weeks of coculture in dishes containing murine stromal cells
(MS5; obtained from Deutsche Sammlung von Mikroorga-
nismen und Zellkulturen) on gelatin-coated glass coverslips
in the serum replacement medium containing DMEM, 15%
knockout serum replacement, and 2mM L-glutamine (all
from Invitrogen). Immunocytochemistry for TUJ1 (neuron-
specific-b-III-tubulin), SOX2, NESTIN, and GFAP was car-
ried out upon appearance of neuron-like structures. For
meso- and endodermal differentiation, iPS cells were de-
tached from the feeder layer by collagenase IV (0.2%) (In-
vitrogen) dispersed into small clumps and cultured in the
differentiation medium (80% Iscove’s modified Dulbecco’s
medium [IMDM] supplemented with 20% fetal calf serum,
1mM L-glutamine, 0.1mM b-mercaptoethanol, and 1%
nonessential amino acids) in ultralow attachment plates
(Corning) for 7 days. Subsequently, EBs were plated onto
0.1% gelatin-coated tissue culture dishes and cultured for
further 14 days.
Immunocytochemistry
Cell cultures were grown on gelatinized coverslips, wa-
shed with PBS, fixed in 80% methanol, and stored at - 20C.
For antibody staining, the coverslips were washed 3 times
with PBS/0.01% Triton-X100, and were then incubated with
the first antibody in PBS/0.01%Triton-X100. The following
antibodies were used: mouse anti-Oct4 (sc-5279, 1:200;
Santa Cruz), mouse anti-Sox2 (H-65, 1:200; Santa Cruz),
mouse anti-Nanog (H-155, 1:200; Santa Cruz) or goat anti-
Nanog (1:50; R&D Systems), mouse anti-cytokeratin 19
[TROMA-III, 1:250; Developmental Studies Hybridoma
Bank(DSHB)), mouse anti-vimentin (AMF17b, 1:500;
DSHB), murine anti-desmin (1:20; Progen Biotechnik), and
goat anti-Sox17 (1:200; R&D Systems). The presence of the
molecules was detected with a goat anti-mouse immuno-
globulin G (IgG) (H + L) Alexa555 conjugated secondary
antibody (A 21424, 1:2,000; Invitrogen Molecular Probes) or
an anti-goat IgG Alexa 555 conjugated secondary antibody,
respectively. In addition, anti-SSEA-1 (1:200) and anti-TRA-
1-60 (1:250) antibodies (both from Millipore) were used in
combination with an anti IgM secondary antibody conju-
gated with Alexa 555. Fibroblasts were used as controls,
and samples without the first or without the secondary
antibody were run in parallel.
Alkaline phosphatase staining
Cells were fixed with 4% formaldehyde, washed with Tris-
buffered saline (with 0.1% Tween-20), and stained with an
alkaline phosphatase (AP) staining solution [46].
Quantitative real-time polymerase chain reaction
Total RNA was prepared using a TriReagent (Ambion)
from Oct4-EGFP fibroblasts (OG2-PFF) and different pas-
sages of iPS cells according to the manufacturer’s instruc-
tions. Isolated total RNA from cell samples was treated
with RNase-free DNase (1U/mg RNA) (Epicentre Bio-
technologies) and 0.5 mg was used for cDNA synthesis. Re-
verse transcription (RT) was performed in a 20 mL volume
consisting of 2mL of 10· RT buffer (Invitrogen), 2mL of
50mM MgCl2 (Invitrogen), 2 mL of 10mM deoxy-tripho-
sphatnucleotides solution (Bioline), 1 mL (20U) of RNAsin
(Applied Biosystems), 1 mL (50U) of moloney murine leu-
kemia virus (MMLV) reverse transcriptase (Applied Biosys-
tems), and 1 mL hexamers (50 mM) (Applied Biosystems). The
samples were incubated at 25C for 10min for primer an-
nealing, and then incubated at 42C for 1 h. Finally, the
samples were heated to 95C for 5min. The cDNA was di-
luted 1:5 and 2mL (10 ng) were used for Real-Time poly-
merase chain reaction (PCR) amplification. Real-Time PCR
was performed in 96-well optical reaction plates (Applied
Biosystems). The PCR mix in each well included 10 mL of 2·
Power SYBR_Green PCR Master Mix (Applied Biosystems),
6.4 mL dH2O, 0.8 mL each of the forward and reverse primers
(5 mM) (Table 1), 2mL of cDNA in a final reaction volume of
20 mL. The PCR reaction was carried out in an ABI 7500 Fast
Real-Time System (Applied Biosystems) using the following
program; activation of the Taq Polymerase for 10min at 95C
followed by 40 cycles of 95C for 15 s and 60C for 1min. The
specificity of the PCR product was confirmed by dissociation
curve analysis and size detection by agarose gel electro-
phoresis. Data generated by the Sequence Detection Software
1.4 were transferred to Microsoft Excel for analysis. For
normalization, the housekeeping genes GAPDH and EEF1A1
were amplified along with the pluripotency-related genes.
Normalization factors were calculated with the excel-based
software genorm (http://medgen.ugent.be/*jvdesomp/
genorm/) based on the housekeeping genes [47].
Western blotting
Total protein isolation was performed by cell lysis in RIPA
buffer on ice for 30min. Equal amounts of the denatured
protein (10mg) were separated by 12% sodium dodecyl sul-
fate–polyacrylamide gels. Proteins were transferred onto
polyvinylidenfluoride membranes (Hybond-P; GE-Health-
care) using a semidry blotting technique. Membranes were
blocked with Tris-buffered saline/0.01% Triton-X100 (TBST)
containing 5% dry milk powder for 1 h. Membranes were
incubated with the primary antibody anti-Oct4 [Santa
Cruz, sc-5279 (1:500)] in TBST with 5% dry milk at room
temperature for 1 hour. Membranes were rinsed with TBST
and incubated with a horseradish peroxidase-coupled sec-
ondary anti-mouse Fab antibody (1:10,000; Sigma) at room
temperature for 1 h. Protein detection was performed with
an enhanced chemoluminescence reagent (ECL plus; GE
Healthcare) and the FusionFX station (VilberLourmat).
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Transfer efficiency was controlled by E7 (tubulin; DSHB)
blotting.
Teratoma formation
To assess the tumorigenic potential of the porcine iPS cells,
1 · 106 cells were subcutaneously injected into the flank of
CD-1 nude mice. The founder animals were obtained from
Charles River, and then maintained in the Institute’s mouse
house according to approved protocols. Mice were analyzed
for tumor formation twice a week, and sacrificed 6–12 weeks
after treatment. Tumors were fixed in 4% formaldehyde and
cryosections were stained with hematoxylin/eosin for his-
tological analyses.
RNA preparation and microarray analysis
Total RNA was extracted using the TRIzol Reagent (In-
vitrogen). After RNA isolation, a DNase I digest was per-
formed. A second cleanup of isolated RNA was done by
extraction with PhOH/CHCl3/Isoamyl and Isoprop/NaOAc
precipitation. The RNA was checked for quantity, purity,
and integrity of the 18S and 28S ribosomal bands by capillary
electrophoresis using the Agilent 2100 bioanalyzer (Agilent
Table 1. Primers for Real-Time Reverse Transcription–Polymerase Chain Reaction
and end point Polymerase Chain Reaction
Gene Primer sequences: 5¢–3¢
Annealing temp./
cycle number
Fragment
size (bp) Accession no.
Porcine AGTGCCCAAAGCCCACTCT 63/40 100 NM_001113060
OCT4 TTCTGGCGACGGTTGCA
Ex4-5
Porcine AAGAACAGCCCAGACCGAGTT 63/40 88 NM_001123197.1
SOX2 GGTTCTCTTGGGCCATCTTG
Porcine GCCACCGACCTGGAGAGT 62/40 59 NM_001031782.1
KLF4 AAGAGCCGGGTTGCTACTG
Porcine GCTGGATTTCCTTCGGATAG 62/40 66 NM_001005154.1
cMYC TTGGTGAAGCTGACGTTGAG
Porcine GCCCCAGCTCCAGTTTCA 60/40 70 NM_001129971.1
NANOG ATTTTCCCCAGCAGTTTCCA
Porcine CAAAAATGACCCACCTATGG 60/40 69 NM_001097418.1
EF1A1 GGCCAGGATGGTTCAGGATA
Porcine ACACTCACTCTTCTACCTTTG 60/40 89 AF017079.1
GAPDH CAAATTCATTGTCGTACCAG
Porcine CCGCGGGCCCGACCTCACGGAACGC
CGCCCTCCTGCAGACCTT
60/40 216 CN028152.1
UTF1
Porcine AGGGAGCTCGTGGTCATCAT 60/40 62 XM_001928051
ESRRB CCCCAGAGAGAGGTTGGAGAA
Porcine GATGCTCCAGTCTATGGCAGAGT 60/40 80 NM_001160273.1
DPPA5 GTGAATTCATGGCTTCCTCAAGTC
Porcine ATGTGCAGAAAACTCTCACG 60/40 203 NM_001044580.1
STAT3 TGGGGTCCCCTTTGTAGCTC
Porcine TGAGATGGAAGGTCGAAGCAT 60/40 100 NM_001114673.1
SAL4 GGTCGCAGGACCAACAAATG
Porcine CTGGAGGTGCACTGCGACTAT 60/40 72 AY785158
TERT GCCCTGGTTGAAGGTGAGACT
Porcine GTCCTGAGAGTGGATGCACAAG 60/40 70 XM_001927029.1
REX1 (ZFP42) CTGTGAACGGAGAGATGCTTTCT
Murine ATCGGACCAGGCTCAGAGGTA 60/40 70 NM_013633.2
Oct4 CCATCCCTCCGCAGAACTC
Murine AAAAGGCCCCCAAGGTAGTG 60/40 70 NM_010849
cMyc TGCTCGTCTGCTTGAATGGA
Endpoint PCR
WNT1 GAGCGCTGTGCGAGAGTGCA 55/32 107 XM_003126100
CCCGACAGCCTCGGTTGACG
TBX20 AGGTACCGCTACGCCTAC 50/32 470 GI 31652229
GTCAGTGAGCCTGGAGGA
SOX17 CGCACGGAGTTTGAACAATA 55/32 167 XM_001928376.4
CAGACGTCGGGGTAGTTACAG
NANOG GGTGGTTAGCTCCTGTTCTCGT 62/35 315 [41]
GAGGGTCTCAGCAGATGACATC
PolyA/POLYA GTTTCCTCGGTGGTGTTTCCTGGGCTATGC 57/35 252 [41]
TGGAGTTCTGTTGTGGGTATGCTGGTGTAA
PCR, polymerase chain reaction.
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Techologies). Only samples with comparable RNA integrity
numbers > 8 were selected for microarray analysis.
Microarrays were done using the Low RNA Input linear
Amplification Kit Plus, One Color protocol (Agilent Tech-
nologies, Inc., 2007; Cat. No.: 5188-5339) and the Agilent
RNA Spike-In Kit for One color (Agilent Technologies, Inc.,
2007; Cat. No.: 5188-5282), according to the manufacturer’s
standard protocol. Global gene expression analysis was ap-
plied using the porcine 4 · 44 K design array from Agilent
Technologies (G2519F; V2: 026440). A total of 200 ng total
RNA was used as a starting material to prepare cDNA. The
cDNA synthesis and in vitro transcription were performed
according to the manufacturer’s recommendation. Quantity
and efficiency of the labeled amplified cRNA were deter-
mined using the NanoDrop ND-1000 UV-VIS spectropho-
tometer version 3.2.1. The hybridizations were performed for
17 h at 10 rpm and 65C in a hybridization oven (Agilent).
Washing and staining of the arrays were done according to
the manufacturer’s recommendation. Cy3 intensities were
detected by one-color scanning using an Agilent DNA mi-
croarray scanner (G2505B) at 5-mm resolution. Scanned im-
age files were visually inspected for artefacts, and then
analyzed.
Intensity data were extracted using Agilent’s Feature Ex-
traction software (version 9.5.3.1). All chips passed the
quality control and were analyzed using the Limma package
of Bioconductor. The data reported in this article were gen-
erated in compliance with the minimum information about a
microarray experiment (MIAME) guidelines.
The microarray data analysis consisted of the following
steps: (1) between-array normalization, (2) global clustering
and principal components analysis (PCA), (3) fitting the data
to a linear model, (4) detection of differential gene expres-
sion, and (5) over-representation analysis of differentially
expressed genes. Quantile-normalization was applied to the
log2-transformed intensity values as a method for between-
array normalization to ensure that the intensities had similar
distributions across arrays.
P values were obtained from the moderate t-statistic and
corrected for multiple testing with the Benjamini–Hochberg
method. The P value adjustment guarantees a smaller number
of false positive findings by controlling the false discovery rate.
FIG. 1. Reprogramming porcine fibroblasts with Sleeping Beauty (SB) transposon vectors. (A) Schematic depiction of experi-
mental design. A SB transposon with a poly-cistronic reprogramming cassette encoding Oct4, Sox2, Klf4, and cMyc, separated by
self-cleaving peptides of foot-and mouth-virus (2A) and the SB100X expression plasmid were co-electroporated into porcine
fibroblasts. (B, C) 10–15 days post-electroporation, cell colonies formed in co-electroporated cultures (arrows). Scale bars= 50mm.
(D) Colony formation was not observed in control cultures (no pOSKM), the same magnification as in (C). (E, F) Comparative
transcriptome analysis of fibroblasts and presumptive porcine iPS cells at passages 18 and 38. (E) Hierarchical cluster analysis;
(F) heat diagram. CAGGS, cytomegalovirus enhancer, chicken b-actin promoter; ITR, inverted terminal repeat; SB100X, hy-
peractive variant of Sleeping Beauty transposase; pOSKM, plasmid carrying SB ITRs and reprogramming factor sequences;
piPS, porcine induced pluripotent stem cells. Color images available online at www.liebertpub.com/scd
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Results
Transposon mediated reprogramming of Oct4-GFP
transgenic porcine fibroblasts
Porcine fibroblasts isolated from Oct4-EGFP transgenic
fetuses (passage 3) were co-electroporated with a SB trans-
poson carrying a multigene cassette consisting of the cDNAs
for Oct4, Sox2, Klf4, and cMyc, separated by self-cleaving 2A
peptide sequences (Fig. 1) and a helper plasmid expressing
the hyperactive variant of Sleeping Beauty transposase
(SB100X). Jumping genes, such as the class II transposon SB,
are mobilized via binding of the transposase to the ITRs,
excision of the ITR flanked region and insertion of this se-
quence into a chromosome [48]. Thereby, a single (mono-
meric) copy of the ITR flanked transposon is integrated into a
genomic locus of the host organism.
About 10–14 days after transposon electroporation, colo-
nies of cells became visible in the porcine cell cultures
(Fig. 1B, C). Mock treatments without plasmid DNA, or only
one plasmid of the nonautonomous transposon, resulted in
no or very few colonies (Table 2). On day 14, the serum-
supplemented culture medium was replaced by the serum-
free medium, supplemented with the knockout serum
replacement and bFGF, and cells were passaged by me-
chanical splitting to gelatinized plates. Starting from day 20
after electroporation, first EGFP-positive cells were detected
(Fig. 2), which were unevenly distributed in the culture
dishes and formed loose colonies (Fig. 2A–C). This obser-
vation was confirmed after staining with AP (Fig. 2D, E).
After proliferation for > 40 passages, the porcine putative iPS
cells grew in sheet-like colonies with expression of the Oct4-
EGFP transgene. The ratio of EGFP-positive cells varied be-
tween 1% and 5% of all cells.
Expression profiling of putative iPS cells
Global gene expression profiling by microarray hybrid-
ization revealed a total of 2,166 upregulated and 2,321
downregulated transcripts in the presumptive iPS cells
Table 2. Summary of Transposon
Electroporation Experiments
Plasmid(s) Ratio
Amount of DNA
(lg/3 · 105 cells)
No of
colonies (d12)
no DNA n.a. n.a. 0
pCMV-SB100X n.a. 5 0
pOSKM n.a. 5 5
pCMV-SB100X 1 2 190
pOSKM 1
pCMV-SB100X 1 5 255
pOSKM 5
pCMV-SB100X 1 4 418
pOSKM 1
pCMV-SB100X 1 10 390
pOSKM 5
(n = 2); n.a., not applicable; CMV, cytomegalovirus immediate
early promoter; SB100X, hyperactive variant of Sleeping Beauty
transposase; pOSKM, transposon plasmid carrying the reprogram-
ming factor sequences.
FIG. 2. Reactivation of
pluripotency reporter Oct4-
EGFP. (A–C) The Oct4-EGFP
construct was reactivated af-
ter transposon plasmid elec-
troporation, the images show
exemplary colonies at 20 days
(A), 25 days (B), and 30 days
(C) after treatment. (A¢–C¢)
Corresponding brightfield
images. Control cultures did
not reveal any EGFP fluores-
cence (not shown). (D, E)
Expression of alkaline phos-
phatase at day 25 after elec-
troporation. EGFP, enhanced
green fluorescent protein.
Color images available online
at www.liebertpub.com/scd
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compared to the originating fibroblasts. Putative porcine iPS
cells were remarkably stable over different passages (Fig. 1E)
and showed expression of stemness-associated genes, such
as LIN28, ZFP42 (REX1), SALL4, and TERT. Real-time RT-
PCR of selected genes confirmed upregulation of en-
dogenous OCT4, SOX2, UTF1, SALL4, ESSRB, REX1, DPPA5
and TERT (Supplementary Fig. S1; Supplementary Data are
available online at www.liebertpub.com/scd), whereas the
porcine KLF4 and cMYC transcripts were downregulated
compared to fibroblast cultures. OCT4, SOX2, UTF1, and
REX1 transcript levels were higher in porcine iPS cells cul-
tured in serum-free medium than in iPS cells maintained in
FIG. 3. Expression of pluri-
potency reporter, OCT4 and
SOX2 in porcine iPS. (A)
Porcine iPS colony with ex-
pression of the Oct4-EGFP
reporter cultured on murine
embryonic fibroblast feeders.
(A) Brightfield, (A¢) EGFP
fluorescence, and (A¢¢) over-
lay. (B) OCT4 expression: (B)
Brightfield, (B¢) OCT4 im-
munohistology, and (B¢¢)
overlay. (C) NANOG expres-
sion: (C) Brightfield, (C¢)
NANOG immunohistology,
and (C¢¢) overlay. Bars = 20
mm. Color images available
online at www.liebertpub
.com/scd
FIG. 4. Transposon-derived
porcine iPS colonies and cells
display typical ultrastructural
features of pluripotent stem
cells. (A) Tightly packed por-
cine iPS cell colony consisting
of cells of uniform morphol-
ogy. Apoptotic bodies are
occasionally seen (arrows).
Inset: Light micrograph of iPS
colony. (B) Porcine iPS cell
presenting a large centrally
located nucleus rich in eu-
chromatin and with a single
large nucleolus (Nu). In the
cytoplasm, sparse mitochon-
dria (M), rough endoplasmic
reticulum (RER), and Golgi
complexes (G) are seen. (C)
Porcine iPS cells in the pe-
riphery of the colony con-
nected by tight junctions (TJ).
(D) Individual porcine iPS
cell showing condensed
chromatin blocks (arrows) pe-
ripherally in the nucleus as a
hallmark of apoptosis. Color
images available online at
www.liebertpub.com/scd
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fibroblast medium. When porcine iPS cells were cultured on
inactivated murine fibroblasts, they formed colonies, which
resembled human iPS cell or ES cell colonies (Fig. 3A). Ex-
pression of OCT4 and NANOG could be confirmed by im-
munocytochemistry (Fig. 3B, C).
The mRNA expression of the exogenous (transposon-
based) multicistronic transcript was determined by species-
specific real-time RT-PCR in feeder free-grown porcine iPS
cells (Supplementary Fig. S2). Western blotting confirmed
the presence of the OCT4 protein in the transposon-treated
cells (Supplementary Fig. S2). However, the primary anti-
body cannot discriminate between the transposon-encoded
transcription factor (Oct4) and the porcine OCT4 homolog. In
addition, expression of endogenous and exogenous stemness
genes were determined by real-time RT-PCR for porcine iPS
cells cultured on MEFs (Supplementary Fig. S3). Expression
of the surface markers, SSEA1 and TRA-1-60, was verified by
indirect immunofluorescence (Supplementary Fig. S4).
Transmission electron microscopy was performed on col-
onies harvested at passage 16. The analysis revealed that the
porcine iPS colonies were compact and composed of cells of
uniform morphology (Fig. 4A). The individual cells pre-
sented a large, centrally located nucleus rich in euchromatin,
typically with a single large nucleolus (Fig. 4B). The cyto-
plasm only rarely contained organelles, including mito-
chondria, rough endoplasmic reticulum, and Golgi
complexes. Cells in the periphery of the colonies were in
some cases connected to each other by tight junctions (Fig.
4C). Apoptotic bodies and cells undergoing apoptosis were
occasionally observed (Fig. 4A, D).
Differentiation in vitro and in vivo
In vitro differentiation experiments toward the neuronal
lineage [45] resulted in rosette formation and cells, which
stained positive for the neuronal progenitor marker NESTIN,
SOX2, and the axonal marker TUJ1, all representing ecto-
dermal cell derivatives (Fig. 5). No specific staining for GFAP
was found (Fig. 5). Putative mesodermal cells could be
identified with antibodies specific for vimentin and desmin;
cells of the endoderm were detected with monoclonal anti-
bodies against the endoderm-specific cytokeratin 19 and
FIG. 5. Directed neuronal
differentiation of porcine iPS
cells. (A–C) Expression of
SOX2 (A), NESTIN (B), and
overlay with nuclear coun-
terstain (C). (D–F) Expression
of the axonal marker TUJ1
(D), GFAP immunoreactivity
(E), and overlay with nuclear
counterstain (F). Scale bar =
20mm. Color images available
online at www.liebertpub
.com/scd
FIG. 6. Expression of mesodermal and endodermal markers.
(A, B) Expression of mesoderm-specific vimentin AMF17B
(A), and nuclear counter stain (B). (C, D) Expression of en-
doderm-specific cytokeratin 19 (C), and nuclear counter stain
(D). Scale bar= 10mm. (E) Expression of TUJ1 and nuclear
counterstain. (F) Expression of SOX17 and nuclear counter-
stain. (G) Expression of desmin and nuclear counterstain.
Bars=40mm. (H) Expression of WNT1, TBX20, and SOX17 at
day 0 and day 20 of differentiation; + , with RT; - , without
RT. Color images available online at www.liebertpub.com/scd
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SOX17 (Fig. 6 and Supplementary Fig. S5). Histochemical
staining with oil red and alizarin indicated differentia-
tion toward adipocytes and cartilage cells (Supplementary
Fig. S6). In all cases, differentiated cells lost their EGFP
fluorescence.
To test their tumorigenic potential, 1 · 106 putative porcine
iPS cells were injected under the skin of 6 immunodeficient
nude mice. In 3 animals, a visible tumor growth was ob-
served 2 weeks later. The animals were sacrificed 6–12 weeks
after injection and the tumor tissue was sectioned and
stained with hematoxylin/eosin. Evidence for the presence
derivatives of the 3 germ layers was found indicating the
formation of true teratomas (Fig. 7). The sections contained
the skeletal muscle, smooth muscle, neuronal, and gland-like
structures. Genotyping with species-specific PCR assays
confirmed the porcine origin of the teratomas (Supplemen-
tary Fig. S7).
Discussion
Here, we used primary fibroblasts derived from Oct4-
EGFP transgenic pigs as pluripotency reporter cells and
demonstrate their usefulness in reprogramming somatic cells
to iPS cells by transposon-mediated delivery of the repro-
gramming factors. The availability of Oct4-EGFP transgenic
pigs allows screening of factors critical for maintenance of
pluripotency and to establishing a culture system that is
compatible with long-term proliferation of porcine pluripo-
tent cells. Under feeder-free conditions, the porcine iPS cells
formed loose colonies. Upon seeding on feeder cells (MEF or
SNL), porcine iPS cells grew in typical dense colonies, re-
sembling the morphology of human iPS cells [2,6].
Ultrastructural analysis revealed that the putative iPS cells
appeared morphologically uniform and displayed charac-
teristics of typical pluripotent cells, including a large nucleus
in a sparse cytoplasm harboring few organelles, a prominent
nucleolus, and an abundant amount of euchromatin [49]. At
the periphery of the colony, adjacent cells were connected by
tight junctions indicating epithelial characteristics; a similar
observation has been made in human ES cells [49].
Attempts to derive true porcine iPS cells have met with
limited success, although chimerism upon blastocyst com-
plementation with porcine iPS cells [28] and germ line
transmission [29] has been reported by one group. Un-
fortunately, both piglets with germline-transmitted repro-
gramming factors died around birth [29].
The lack of true porcine ES cells prevents the unequivocal
identification of pluripotent cells after reprogramming to-
ward iPS cells in this species. In contrast, the available mouse
and human ES cells clearly facilitated the development
of protocols for cellular reprogramming in these species
[16,50]. In reprogrammed human cells, colonies with phe-
notypes that resemble true ES cells differed with regard to
molecular marker expression and differentiation potential
[51]. By analyzing expression of pluripotency markers, the
methylation status at the OCT4 and NANOG promoters, and
the differentiation potential into teratomas, true iPS cells
could be discriminated from cells that were not completely
reprogrammed [51]. Mouse reprogramming studies were
facilitated by the use of pluripotency reporter gene
FIG. 7. Teratoma formation
in nude mice. (A–C) Histolo-
gical sections of tumors de-
rived after subdermal injection
in nude mice at low magnifi-
cation. Several cell types are
discernible after hematoxylin/
eosin staining. Muscle cells
[arrows (A–C)], neuronal cells
(arrowhead), and presumptive
endocrine cells (asterisk) are
intermingled with compact
cell clusters (#). Bar = 80mm.
(D–K) Histological sections at
high magnification. (D)
Smooth muscle cells, (E) stri-
ated muscle fiber (longitudinal
and cross sections), (F) duct-
like structures, (G) squamous
tissue, (H–I) gland like struc-
tures, ( J–K) neuron-like struc-
tures. Bar = 50mm. Color
images available online at
www.liebertpub.com/scd
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constructs, driven by either the Fbx15, Oct4, or Nanog pro-
moter, and nascent iPS cells could successfully be identified
[1,3,4,13]. Culture conditions for long-term maintenance of
pluripotency in murine cells are well defined [52]. Recent
findings indicate that long-term maintenance of pluripotency
of murine ES and iPS cells depends on the presence of a rare
two-cell (2C) stage [53].
In the present study, we used somatic cells from Oct4-
EGFP transgenic pigs, and show that this facilitated repro-
gramming, thus representing a valuable tool for studies into
the reprogramming of somatic cells into iPS cells. Experi-
ments have been initiated to excise the reprogramming SB-
transposon to generate foot print-free porcine iPS cells. In PB
reprogrammed murine iPS, the traceless removal of a re-
programming transposon has been shown [54]. Recently, the
suitability of SB-mediated reprogramming of murine fibro-
blasts to iPS cells has been demonstrated [55].
The transposon-mediated reprogramming reported here has
distinct advantages over viral approaches reported previously
[25–28]. Transposon plasmid preparation is straightforward
and does not require additional security precautions, as for
retro- and lentiviral vectors. The SB transposase catalyzes
integration into the host genome in a randommanner, without
preference for promoter or exonic regions, thus reducing the
risk of insertional mutagenesis [54,56,57].
In conclusion, results of the present study demonstrate
the usefulness of porcine Oct4-EGFP cells and transposon-
mediated reprogramming for the derivation of porcine iPS
cells. However, this study also highlights the limitations of
current culture systems. Variable cell morphology in different
passages and a low ratio of Oct4-EGFP-positive cells indicated
that maintenance of pluripotency in reprogrammed porcine
cells is not yet fully achieved under the present conditions.
Most likely this is due to the culture conditions and culture
media, which were adapted from work with human and
mouse pluripotent cells. The remarkable differences between
human and murine pluripotent cells [58–61] suggest that
porcine iPS require species-specific media and growth factor
supplements. A molecular basis for this different respon-
siveness to culture conditions could be the species-specific
expression of regulatory micro-RNAs (miRNA); certain miRNA-
clusters are correlated with stemness and ensure fine tuning
of post-transcription regulatory networks [62]. Nevertheless,
results of this study set the basis for in-depth studies on
pluripotency sustaining factors in porcine cells.
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